On Monday, Kite Pharma Inc (NASDAQ:KITE)’s shares declined -9.81% to $58.68.
NeoStem, Inc. (NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, declared recently the expansion of manufacturing services under an existing Services Contract between its wholly-owned partner, PCT, and Kite Pharma, Inc. (KITE) (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
Etsy Inc (NASDAQ:ETSY)’s shares dropped -9.72% to $24.90.
Etsy Inc (ETSY) commenced on The Nasdaq Stock Market on April 16, 2015.
Founded in 2005 and headquartered in Brooklyn, NY, Etsy is a marketplace where people around the world connect, both online and offline, to make, sell and buy unique goods.
As of December 31, 2014, Etsy has connected 54 million members, counting 1.4 million active sellers and 19.8 million active buyers, in nearly every country in the world. On Etsy, creative entrepreneurs find meaningful work and both global and local markets for their goods, and thoughtful consumers discover and buy unique goods and build relationships with the people who sell them.
Etsy, Inc. operates online and offline marketplaces to buy and sell handmade items, vintage goods, and craft supplies. Its platform connects sellers and buyers to sell or buy products for art, home and living, mobile accessories, jewelry, wedding, and others.
At the end of Monday’s trade, Nektar Therapeutics (NASDAQ:NKTR)‘s shares dipped -8.28% to $10.96.
Nektar Therapeutics (NKTR) stated recently that partner Baxter International Inc. declared that the company has presented a new drug application (NDA) to Japan’s Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
Gevo, Inc. (NASDAQ:GEVO), ended its Monday’s trading session with 1,331.27% gain, and closed at $2.65.
Gevo, Inc. (GEVO) declared its financial results for the three months ended December 31, 2014 and offered an update on recent corporate highlights.
In the fourth quarter of 2014, Gevo continued to progress the commercial operation of isobutanol at Luverne under the Side-by-Side mode of production (SBS), meeting its stated milestone in December 2014 of producing greater than fifty thousand gallons of isobutanol in one month. This achievement was a result of the introduction of Gevo’s second-generation yeast biocatalyst at the plant, in addition to noteworthy process improvements learned by Gevo since switching the plant to SBS production earlier in 2014.
Gevo, Inc., a renewable chemicals and biofuels corporation, focuses on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
